🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University201 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School89 Nanjing First Hospital, Nanjing Medical University68 The Second Hospital of Nanjing Medical University32 Nanjing Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanjing

1193 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
NCT06764238Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
1,800
Hefei, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha, Nanjing
2025-01-03
Recruiting
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT06745622Paroxysmal Nocturnal Hemoglobinuria
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
47
Nanjing
2025-01-03
By invitation
Band Versus Ring for Tricuspid Regurgitation
NCT04093297Tricuspid Regurgitation
Nanjing Medical University
Not applicable
300
Nanjing
2025-01-01
Not yet open
Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery
NCT06723366Cardio-pulmonary Bypass, Cardiovascular Surgery, Cerebral Protection, Brain Injury
Nanjing Medical University
Not applicable
120
Beijing, Nanjing
2025-01-01
Recruiting
Diaphragmatic Function and Respiratory Drive in OSA and COPD
NCT07003399Obstructive Sleep Apnea
Nanjing Medical University
Observational
80
Nanjing
2025-01-01
Recruiting
The Value of a Convolutional Neural Network-Based Renal Artery Perfusion Model in Predicting Renal Function After Partial Nephrectomy: A Prospective Study
NCT06751498Renal Cell Cancer
Shao Pengfei
Observational
300
Nanjing
2025-01-01
Recruiting
Optimising Renal Tumour Management Through Artificial Intelligence Modules
NCT06714916Renal Neoplasms, Pathology, Renal Cell Cancer
Shao Pengfei
Observational
2,100
Nanjing
2025-01-01
By invitation
Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)
NCT04444362Cardiovascular Disease, Cardiopulmonary Bypass
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu, Shanghai
2025-01-01
Not yet open
Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)
NCT06730802Myocardial Ischaemic Syndrome, Coronary Heart Disease
Nanjing Medical University
Not applicable
400
Beijing, Nanjing
2025-01-01
Recruiting
Intravenous Hydromorphone for the Treatment of Acute Pain
NCT06949059Acute Chest Pain
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
30
Nanjing
2025-01-01
Recruiting
Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy
NCT07113613Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
150
Nanjing
2025-01-01
Recruiting
To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)
NCT06817954Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
800
Nanjing
2025-01-01
Recruiting
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
NCT07394387Triple Negative Breast Cancer (TNBC)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
58
Nanjing
2025-01-01
Recruiting
Optic Nerve Injury in Obstructive Sleep Apnea Patients
NCT06748703Obstructive Sleep Apnea (OSA), Ischemic Optic Neuropathy/Optic Nerve Stroke
Nanjing Medical University
Not applicable
80
Nanjing
2025-01-01
Recruiting
Washed Microbiota Transplantation for Food Intolerance
NCT07190183Food Intolerance
The Second Hospital of Nanjing Medical University
Observational
100
Nanjing
2025-01-01
Recruiting
Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study
NCT07097805Type 1 Diabetes (T1D)
Second Xiangya Hospital of Central South University
Not applicable
3,000
Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu
2025-01-01
Recruiting
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
NCT07586787Proliferative Diabetic Retinopathy (PDR)
Xiamen Ophthalmology Center Affiliated to Xiamen University
Not applicable
100
Beijing, Xiamen, Zhengzhou, Nanjing, Dalian
2025-01-01
Not yet open
An Observational Clinical Study on the Construction of an Artificial Neural Network Model for ICU Pneumonia
NCT06661499Pneumonia
Chinese Medical Association
Observational
600
Nanjing
2025-01
Not yet open
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
NCT06779461Hepatocellular Carcinoma Non-Resectable
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Recruiting
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
NCT07195799Non-Hodgkin Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
180
Nanjing
2024-12-31
Recruiting
A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06912165Brief Description of Focus of Study
Zhejiang Wenda Pharma Technology LTD.
Phase 2
140
Nanjing
2024-12-31
Recruiting
Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
NCT06849180Combined Hepatocellular-cholangiocarcinoma, Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Zhongda Hospital
Observational
198
Nanjing
2024-12-31
Not yet open
Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM
NCT06762223Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
Xiqiao Zhou
Phase 4
190
Nanjing
2024-12-31
Recruiting
Effect of Subanesthetic Dose of Esketamine on Sleep Quality
NCT06773143Insomnia, Breast Cancer Surgery, Esketamine
Nanjing First Hospital, Nanjing Medical University
Not applicable
184
Nanjing
2024-12-30
Recruiting
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT06723080Moderate to Severe Atopic Dermatitis
Jiangsu vcare pharmaceutical technology co., LTD
Phase 3
480
Nanjing
2024-12-30
Recruiting
Efficacy and Olfactory Network of Electro-acupuncture for Subjective Cognitive Decline
NCT06758154Subjective Cognitive Decline (SCD)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
92
Nanjing
2024-12-28
Recruiting
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
NCT06751134Neuroblastoma, Recurrent, Refractory
Nanjing Children's Hospital
Phase 1
12
Nanjing
2024-12-28
Recruiting
Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
NCT07195500Neuroblastoma, Pheochromocytoma, Paraganglioma
Nanjing First Hospital, Nanjing Medical University
Observational
30
Nanjing
2024-12-25
Recruiting
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
NCT06747156Autoimmune Diseases
Ruijin Hospital
Phase EARLY_PHASE1
66
Wuhan, Nanjing, Shanghai
2024-12-23
Recruiting
Neuroprotective Effects of Long-term TaVNS in Early Parkinson's Disease Patients
NCT06665113Parkinson Disease, Idiopathic
Kezhong Zhang
Not applicable
12
Nanjing
2024-12-23
Recruiting
Removable Titanium Clip Treatment for Acute Variceal Hemorrhage from the Gastric Fundus
NCT06736314Gastric Variceal Bleeding
Shupei Li
Not applicable
10
Nanjing
2024-12-20
Recruiting
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
NCT06715007Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity
The First Affiliated Hospital with Nanjing Medical University
Observational
300
Nanjing
2024-12-20
Not yet open
Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis
NCT06741800Rhinitis, Allergic
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2024-12-20
Recruiting
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
NCT06725381Solid Malignancies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
138
Guangzhou, Nanning, Wuhan, Changsha, Nanjing, Jinan, Linyi, Chengdu
2024-12-17
Recruiting
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
NCT06727812Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1
206
Nanjing, Chengdu
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
Double Pig Tail Stent-assisted Fixation of Fully Covered Metal Stents for the Treatment of Benign Duodenal Strictures
NCT06736301Benign Duodenal Stricture
Shupei Li
Not applicable
5
Nanjing
2024-12-15
Recruiting
Clinical Trial of TQB3002 in Patients With Advanced Cancers
NCT06662760Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xi’an, Chengdu
2024-12-09
Not yet open
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
NCT06699498Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, PD-L1, Anlotinib
The First Affiliated Hospital with Nanjing Medical University
Phase 2
45
Nanjing
2024-12-03
Active, closed
Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ
NCT06739161Gastroesophageal Junction Adenocarcinoma
Jiangsu Cancer Institute & Hospital
Phase 2
120
Nanjing
2024-12-02
Not yet open
Protective Effect of RIPC Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery (Panda VII)
NCT06707350Cardiopulmonary Bypass, Cardiovascular Diseases, Inflammatory Response During Cardiac Surgery
Nanjing Medical University
Not applicable
500
Nanjing
2024-12-01
Active, closed
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
NCT06939439Gastric Cancer Stage III
The First Affiliated Hospital with Nanjing Medical University
Phase 3
416
Nanjing
2024-12-01
Recruiting
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
NCT06735287Bladder Cancer, NMIBC
The First Affiliated Hospital with Nanjing Medical University
Not applicable
60
Nanjing
2024-12-01
By invitation
Correlation Analysis of Xpert Carba-R Detection of Non-colonized CRE in BALF and Rectal Swabs From Patients With LRTI
NCT06636890Carbapenem-Resistant Enterobacteriaceae, Lower Respiratory Tract Infections
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2024-12-01
Recruiting
Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors
NCT06908902RCC, Renal Cell Cancer, Partial Nephrectomy
The First Affiliated Hospital with Nanjing Medical University
Not applicable
60
Nanjing
2024-12-01
Recruiting
Comparing the Incidence of Parastomal Hernia After Mesenteric Molding Suturing and Non-molding Suturing in Colostomy Surgery
NCT06674187Parastomal Hernia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
234
Nanjing
2024-12-01
Not yet open
Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer
NCT06662708Prostate Cancer, Prostate Intraductal Carcinoma, Prostate Cancer Aggressiveness, Prostate Cancer Stage
Shao Pengfei
Not applicable
200
Nanjing
2024-12-01
Not yet open
Microbial Study of Sublingual Immunotherapy Spray in Patients With Allergic Rhinitis
NCT06741787Rhinitis, Allergic
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2024-12
Not yet open
Study on the Effect and Mechanism of Aescine Sodium in the Treatment of Allergic Rhinitis
NCT06709079Allergic Rhinitis
Cheng Lei
Not applicable
60
Nanjing
2024-12
Not yet open
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
NCT06684158GC/GEJC
The First Affiliated Hospital with Nanjing Medical University
Phase 2
70
Nanjing
2024-11-30
Active, closed
Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)
NCT07157605Pancreatic Cancer Resectable, Pancreatectomy
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Observational
94
Nanjing
2024-11-28
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Recruiting
Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
NCT07056010Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
30
Nanjing
2024-11-25
Not yet open
Washed Microbiota Transplantation in Solid Organ Transplantation
NCT06708676Solid Organ Transplant Complications
The Second Hospital of Nanjing Medical University
Not applicable
50
Nanjing
2024-11-20
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
NCT06361238Delirium, Postoperative
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
260
Nanjing
2024-11-19
Recruiting
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
NCT06685289Biliary Malignant Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase 2
70
Nanjing
2024-11-15
Recruiting
Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
NCT06895447Gastric Cancers
The First Affiliated Hospital with Nanjing Medical University
Phase 2
40
Nanjing
2024-11-14
Recruiting
Impact of Pet Cats on Nasal and Gut Microbiota in Patients With Cat Allergen Allergy
NCT07110311Allergic Rhinitis
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2024-11-14
Active, closed
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2
94
Fuzhou, Zhengzhou, Changzhou, Nanjing, Shanghai, Hangzhou
2024-11-14
Active, closed
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.
NCT07212426PNH - Paroxysmal Nocturnal Hemoglobinuria
Longbio Pharma
Phase 2
30
Nanjing
2024-11-14
By invitation
Multicenter Prospective Cohort Study of Hypertriglyceridemia Acute Pancreatitis
NCT06976099Acute Pancreatitis (AP), Hypertriglyceridemia Acute Pancreatitis
Peking Union Medical College Hospital
Observational
1,000
Beijing, Guangzhou, Zunyi, Harbin, Changsha, Nanjing, Yangzhou, Dalian
2024-11-13
Recruiting
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes
NCT06825182Type 2 Diabetes Mellitus
Nanjing First Hospital, Nanjing Medical University
Phase 3
1,000
Nanjing
2024-11-07
Recruiting
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
NCT06643793Colorectal Neoplasms Malignant
Affiliated Hospital of Nantong University
Phase 2
30
Nanjing
2024-11-04
Active, closed
Correlation of Preoperative Indices (serum Vit D, Calcium, Phosphorus, FAR, PLR, SII) on Intraoperative Bleeding in CRS
NCT06737198Chronic Rhinosinusitis (CRS) with and Without Nasal Polyps
Nanjing First Hospital, Nanjing Medical University
Observational
100
Nanjing
2024-11-01
Recruiting
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study
NCT06770296Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 1
200
Nanjing
2024-11-01
Not yet open
1.Comparison of the Analgesic Effect of Remifentanil Group and Different Dose Groups of Oliceridine in Postoperative Patients Undergoing Cardiac Surgery 2.Exploring the Hemodynamic Effects of Analgesic Regimens With Different Doses of Oliceridine After Cardiac Surgery
NCT06619145Oliceridine, Postoperative Cardiac Surgery
Nanjing First Hospital, Nanjing Medical University
Phase 4
270
Nanjing
2024-11-01
Recruiting
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
NCT07054879Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
70
Nanjing
2024-11-01
Recruiting
Rapid dFLC Response Predict CHR in AL Amyloidosis
NCT06627309Systemic AL Amyloidosis
Peking University People's Hospital
Observational
50
Beijing, Harbin, Nanjing, Shenyang, Xi'an
2024-10-26
Recruiting
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
NCT06456528Cancer Treatment-Induced Thrombocytopenia
Qilu Pharmaceutical Co., Ltd.
Phase 2/3
235
Harbin, Nanjing
2024-10-22
Recruiting
Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma
NCT07202156Melasma (Facial Melasma)
The First Affiliated Hospital with Nanjing Medical University
Not applicable
35
Nanjing
2024-10-20
By invitation
Clinical Classification and Imaging Markers in Patients of Obesity
NCT06649071Obesity, fMRI, Clinical Classification
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
100
Nanjing
2024-10-20
Recruiting
Washed Microbiota Transplantation for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract
NCT05439135Malnutrition, Gastroenterostomy
The Second Hospital of Nanjing Medical University
Not applicable
62
Nanjing
2024-10-20
Recruiting
Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy
NCT06090994Colorectal Cancer
Fudan University
Phase 4
756
Harbin, Changzhou, Nanjing, Yangzhou, Shanghai, Hangzhou, Ningbo
2024-10-18
Not yet open
An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
NCT06645197Amyotrophic Lateral Sclerosis (ALS)
Peking University Third Hospital
Phase EARLY_PHASE1
7
Beijing, Fujian, Nanjing, Chengdu, Hangzhou
2024-10-16
Active, closed
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
NCT06766019Pancreatic Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
47
Nanjing
2024-10-16
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
Boehringer Ingelheim
Phase 2
588
Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan
2024-10-11
Recruiting
Clinical Study of Perioperative Sleep Disorders in Cardiac Surgery
NCT06778811Sleep Wake Disorders, Esketamine and the Quality of Recovery, Dexmedetomidine
Nanjing First Hospital, Nanjing Medical University
Phase 4
180
Nanjing
2024-10-11
Active, closed
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)
NCT06577194Rectal Cancer, Advanced Solid Tumor
The First Affiliated Hospital with Nanjing Medical University
Phase 2
35
Nanjing
2024-10-09
Not yet open
Multi Center Clinical Study on the Lipid-lowering Efficacy and Safety of Menggongzi Tibetan Tea Special Drink
NCT06551298Hyperlipidemias
The First Affiliated Hospital with Nanjing Medical University
Not applicable
129
Nanjing
2024-10-01
Recruiting
The Effect of Interventions for Health Behaviors in Hypertensive Patients
NCT06640751Hypertension, Health Behavior, Public Health
Nanjing Medical University
Not applicable
240
Nanjing
2024-10-01
Recruiting
Interventional Treatment of Chronic Tinnitus With Acoustic Stimulation
NCT07185061Chronic Tinnitus
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2024-10-01
Not yet open
Multi-parametric Functional MRI in Patients of Chronic Kidney Disease
NCT06639685Chronic Kidney Disease(CKD), MRI
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2024-10-01
Not yet open
Application of Electronic Endoscope in Fetal Distress
NCT06608654Fetal Distress, Fetal Hypoxia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
15
Nanjing
2024-10-01
Not yet open
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
NCT06594432Diffuse Large B Cell Lymphoma (DLBCL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
40
Nanjing
2024-10
Recruiting
Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer
NCT06584279Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
563
Nanjing
2024-10
Not yet open
Influence of Different Prostheses on Postoperative Clinical Function in Total Knee Arthroplasty
NCT06617819Knee Arthropathy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
40
Nanjing
2024-09-30
By invitation
Clinical Trial of Anovulatory Infertility
NCT06601452Polycystic Ovary Syndrome, Diminished Ovarian Reserve, Ovulation Disorder
Affiliated Hospital of Nanjing University of Chinese Medicine
Phase EARLY_PHASE1
650
Nanjing
2024-09-30
Recruiting
Brachial Versus Femoral Access for Carotid Artery Stenting
NCT06557135Carotid Artery Stenosis Without Infarction (Disorder), Ischemic Stroke
The First Affiliated Hospital with Nanjing Medical University
Not applicable
226
Nanjing
2024-09-27
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Recruiting
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
NCT06492460Squamous Cell Carcinoma of Head and Neck
Sun Yat-sen University
Phase 3
422
Guangzhou, Guilin, Changsha, Nanjing
2024-09-20
Recruiting
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
NCT06607276Cholangiocarcinoma Cancer, Adebrelimab (SHR-1316)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
122
Nanjing, Xuzhou, Yancheng
2024-09-20
Not yet open
To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection
NCT06561594Idiopathic Hypogonadotropic Hypogonadism
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Recruiting
Adebrelimab and Chidamide for Pancreatic Cancer
NCT06584227Pancreatic Cancer, Adult
Liu Xiufeng
Phase 2
45
Nanjing
2024-09-10
Recruiting
TACE With Thermosensitive Nanogel Versus Embosphere for HCC
NCT06593964Unresectable Hepatocellular Carcinoma
Zhongda Hospital
Not applicable
188
Nanjing
2024-09-10
Active, closed
Evaluate the Efficacy and Safety of SASI Compared with RYGB in the Treatment of Obesity and Related Metabolic Diseases
NCT06598267Bariatric Surgery
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
304
Nanjing
2024-09-03
Recruiting
Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition
NCT06512584Short Bowel Syndrome
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
72
Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xi’an
2024-09-03
Recruiting
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252Gastric Cancer
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Active, closed
Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06853769Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
48
Nanjing
2024-09-01
Rows per page Showing 601–700 of 1193
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing?page=7

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,193 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

713 of the 1,193 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 232 have not yet opened recruitment, 216 are active but closed to new participants, and 32 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.